WallStreetZenWallStreetZen

NASDAQ: VTGN
Vistagen Therapeutics Inc Stock

$3.52+0.00 (+0%)
Updated Jun 14, 2024
VTGN Price
$3.52
Fair Value Price
$6.03
Market Cap
$95.13M
52 Week Low
$1.62
52 Week High
$24.71
P/E
-2.32x
P/B
0.83x
P/S
96.05x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.06M
Earnings
-$29.36M
Gross Margin
100%
Operating Margin
-2,759.21%
Profit Margin
-2,759.6%
Debt to Equity
0.08
Operating Cash Flow
-$26M
Beta
1.57
Next Earnings
Jun 26, 2024
Ex-Dividend
N/A
Next Dividend
N/A

VTGN Overview

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VTGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VTGN ($3.52) is undervalued by 41.59% relative to our estimate of its Fair Value price of $6.03 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
VTGN ($3.52) is significantly undervalued by 41.59% relative to our estimate of its Fair Value price of $6.03 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
VTGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VTGN due diligence checks available for Premium users.

Be the first to know about important VTGN news, forecast changes, insider trades & much more!

VTGN News

Valuation

VTGN fair value

Fair Value of VTGN stock based on Discounted Cash Flow (DCF)
Price
$3.52
Fair Value
$6.03
Undervalued by
41.59%
VTGN ($3.52) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VTGN ($3.52) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VTGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VTGN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.32x
Industry
-10.23x
Market
30.51x

VTGN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.83x
Industry
6.25x
VTGN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VTGN's financial health

Profit margin

Revenue
$197.3k
Net Income
-$9.5M
Profit Margin
-4,825.8%
VTGN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
VTGN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$123.7M
Liabilities
$9.4M
Debt to equity
0.08
VTGN's short-term assets ($120.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VTGN's short-term assets ($120.67M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VTGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VTGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.2M
Investing
-$28.7k
Financing
-$167.8k
VTGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VTGN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
VTGN$95.13M0.00%-2.32x0.83x
DBVT$96.24M-3.11%-1.22x0.86x
EPRX$96.72M-1.63%N/A4.95x
ATHA$97.35M-0.39%-0.83x0.91x
ARMP$97.62M-5.92%-1.23x-1.73x

Vistagen Therapeutics Stock FAQ

What is Vistagen Therapeutics's quote symbol?

(NASDAQ: VTGN) Vistagen Therapeutics trades on the NASDAQ under the ticker symbol VTGN. Vistagen Therapeutics stock quotes can also be displayed as NASDAQ: VTGN.

If you're new to stock investing, here's how to buy Vistagen Therapeutics stock.

What is the 52 week high and low for Vistagen Therapeutics (NASDAQ: VTGN)?

(NASDAQ: VTGN) Vistagen Therapeutics's 52-week high was $24.71, and its 52-week low was $1.62. It is currently -85.75% from its 52-week high and 117.28% from its 52-week low.

How much is Vistagen Therapeutics stock worth today?

(NASDAQ: VTGN) Vistagen Therapeutics currently has 27,025,209 outstanding shares. With Vistagen Therapeutics stock trading at $3.52 per share, the total value of Vistagen Therapeutics stock (market capitalization) is $95.13M.

Vistagen Therapeutics stock was originally listed at a price of $123.26 in May 11, 2016. If you had invested in Vistagen Therapeutics stock at $123.26, your return over the last 8 years would have been -97.14%, for an annualized return of -35.88% (not including any dividends or dividend reinvestments).

How much is Vistagen Therapeutics's stock price per share?

(NASDAQ: VTGN) Vistagen Therapeutics stock price per share is $3.52 today (as of Jun 14, 2024).

What is Vistagen Therapeutics's Market Cap?

(NASDAQ: VTGN) Vistagen Therapeutics's market cap is $95.13M, as of Jun 16, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Vistagen Therapeutics's market cap is calculated by multiplying VTGN's current stock price of $3.52 by VTGN's total outstanding shares of 27,025,209.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.